Medicine, Ayurvedic

医学 ,阿育吠陀
  • 文章类型: Journal Article
    背景:哮喘是一种异质性疾病,具有几种表型和内生型的炎症性疾病。严重的哮喘患者通常表现为混合粒细胞缺乏症,皮质类固醇敏感性降低。支气管是一种新开发的阿育吠陀处方药,用于治疗阻塞性气道疾病。本研究的目的是评估支气管在混合粒细胞哮喘小鼠模型中的体内疗效。
    方法:采用高效薄层色谱法(HPTLC)和超高效液相色谱法(UHPLC)鉴定和定量支气管中存在的植物代谢产物。在小鼠室内尘螨(HDM)和完全弗氏佐剂(CFA)诱导的混合粒细胞哮喘模型中评估支气管的临床前有效性。平行测试高剂量地塞米松。用HDM和CFA免疫无特异性病原体的C57BL/6小鼠,19天后,他们连续4天接受HDM鼻内攻击.然后用雾化乙酰甲胆碱攻击小鼠以评估气道高反应性(AHR)。在支气管肺泡灌洗液(BALF)中计数炎症细胞流入,然后进行肺组织学检查。此外,通过多重免疫试验评估BALF中Th2和促炎细胞因子的浓度.还在肺中评估促炎细胞因子和粘蛋白5AC(MUC5AC)的mRNA表达。
    结果:支气管的HPTLC指纹和UHPLC定量显示存在生物活性植物代谢物,即,迷迭香酸,没食子酸,没食子酸甲酯,胡椒碱,丁香酚和甘草甜素。支气管有效地减少了由HDM-CFA驱动的AHR和总白细胞的流入,BALF中的嗜酸性粒细胞和嗜中性粒细胞。此外,支气管抑制炎症细胞在肺中的浸润以及杯状细胞化生。Further,它还抑制了BALF中Th2细胞因子和促炎细胞因子水平的升高。同样,支气管还调节小鼠肺中促炎细胞因子以及MUC5AC的mRNA表达。降低高剂量类固醇的有效性,在模型中观察到地塞米松。
    结论:我们首次在HDM和CFA诱导的混合粒细胞性哮喘动物模型中证明了草药矿物药物的强大药理作用。结果表明支气管在具有混合粒细胞表型的严重哮喘患者中的潜在效用。
    BACKGROUND: Asthma is a heterogeneous, inflammatory disease with several phenotypes and endotypes. Severe asthmatics often exhibit mixed granulocytosis with reduced corticosteroid sensitivity. Bronchom is a newly developed Ayurvedic prescription medicine, indicated for the treatment of obstructive airway disorders. The purpose of the present study was to evaluate the in-vivo efficacy of Bronchom in mouse model of mixed granulocytic asthma with steroidal recalcitrance.
    METHODS: High-performance thin layer chromatography (HPTLC) and Ultra-high performance liquid chromatography (UHPLC) were employed to identify and quantitate the phytometabolites present in Bronchom. The preclinical effectiveness of Bronchom was assessed in house dust mite (HDM) and Complete Freund\'s adjuvant (CFA)-induced mixed granulocytic asthma model in mice. High dose of dexamethasone was tested parallelly. Specific-pathogen-free C57BL/6 mice were immunized with HDM and CFA and nineteen days later, they were intranasally challenged with HDM for four consecutive days. Then the mice were challenged with nebulized methacholine to evaluate airway hyperresponsiveness (AHR). Inflammatory cell influx was enumerated in the bronchoalveolar lavage fluid (BALF) followed by lung histology. Additionally, the concentrations of Th2 and pro-inflammatory cytokines was assessed in the BALF by multiplexed immune assay. The mRNA expression of pro-inflammatory cytokines and Mucin 5AC (MUC5AC) was also evaluated in the lung.
    RESULTS: HPTLC fingerprinting and UHPLC quantification of Bronchom revealed the presence of bioactive phytometabolites, namely, rosmarinic acid, gallic acid, methyl gallate, piperine, eugenol and glycyrrhizin. Bronchom effectively reduced AHR driven by HDM-CFA and the influx of total leukocytes, eosinophils and neutrophils in the BALF. In addition, Bronchom inhibited the infiltration of inflammatory cells in the lung as well as goblet cell metaplasia. Further, it also suppressed the elevated levels of Th2 cytokines and pro-inflammatory cytokines in the BALF. Similarly, Bronchom also regulated the mRNA expression of pro-inflammatory cytokines as well as MUC5AC in mice lungs. Reduced effectiveness of a high dose of the steroid, dexamethasone was observed in the model.
    CONCLUSIONS: We have demonstrated for the first time the robust pharmacological effects of an herbo-mineral medicine in an animal model of mixed granulocytic asthma induced by HDM and CFA. The outcomes suggest the potential utility of Bronchom in severe asthmatics with a mixed granulocytic phenotype.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Systematic Review
    背景:下背部和颈部疼痛是常见的肌肉骨骼疾病,有多种治疗选择。印度的传统医疗系统,被称为阿尤什(阿育吠陀,瑜伽和自然疗法,Unani,西达,Sowa-Rigpa和同病)提供了一系列干预措施,并被广泛使用。鉴于Ayush干预腰椎和颈椎病后不良事件的文献有限,我们综合了证据并估计了报告不良事件的研究比例.
    方法:我们系统地搜索了从生物医学和多学科摘要和引文数据库以及Ayush特定存储库(从成立到2021年4月)的所有已发布文档。我们根据纳入标准选择了研究,并提取了信息,遵守PRISMA准则。我们系统地回顾了选定研究的定性证据。
    结果:在选定的113项研究中,大多数(94%)是介入研究,包括77篇(68.1%)期刊论文和35篇(31%)学术论文。在Ayush系统中,相当比例来自阿育吠陀(32.7%),其次是西达(24.8%),瑜伽(22.1%)Unani(15.9%)和同种病(4.4%)。几乎四分之三的研究是关于腰椎病的(65%;n=74),其次是颈椎病(31%;n=35),其余四个包括两个。113项研究中有13%描述了不良事件[瑜伽=9.7%;Unani=1.8%和同种病=1.8%]。与颈椎病(2.7%)相比,腰椎研究中报告的不良事件更多(9.7%)。干预的性质是非药物干预(10.6%;n=12),药理学(n=2;1.8%)或联合(n=1;0.9%)。
    结论:8项研究中只有1项报告了在Ayush干预颈椎和腰椎病后出现的不良事件。不良事件可能存在一定程度的漏报,需要进一步探索。PROSPERO注册IDCRD42020167433。
    BACKGROUND: Low back and neck pain are common musculoskeletal disorders with multiple treatment options. India\'s traditional medical systems, known as Ayush (Ayurveda, Yoga and Naturopathy, Unani, Siddha, Sowa-Rigpa and Homoeopathy) offer range of interventions and are widely used. In view of limited documentation of adverse events following Ayush interventions for lumbar and cervical spondylosis, we synthesized evidence and estimated proportion of studies reporting adverse events.
    METHODS: We systematically searched all published documents from biomedical and multidisciplinary abstract and citation databases and Ayush-specific repositories from their inception to April 2021. We selected studies as per inclusion criteria and extracted information, adhering to PRISMA guidelines. We systematically reviewed the qualitative evidence form the selected studies.
    RESULTS: Majority (94%) of the selected 113 studies were interventional studies and included 77 (68.1%) journal articles and 35 (31%) academic dissertations. Among the Ayush systems, considerable proportion was from Ayurveda (32.7%), followed by Siddha (24.8%), Yoga (22.1%), Unani (15.9%) and Homoeopathy (4.4%). Almost three-fourths of the studies were on lumbar spondylosis (65%; n = 74), followed by cervical spondylosis (31%; n = 35), and the remaining four included both. Thirteen percent of the 113 studies described adverse events [Yoga = 9.7%; Unani = 1.8% and Homoeopathy = 1.8%]. More adverse events were reported among the studies on lumbar (9.7%) than cervical spondylosis (2.7%). The nature of interventions were non-pharmacological (10.6%; n = 12), pharmacological (n = 2; 1.8%) or combined (n = 1; 0.9%).
    CONCLUSIONS: Only one in eight studies reported any adverse event following Ayush interventions for cervical and lumbar spondylosis. There could be certain degree of underreporting of adverse events and requires further exploration. PROSPERO Registration ID CRD42020167433.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    每年都有大量人因结核病(TB)而丧生,这是一种由结核分枝杆菌引起的古老疾病。结核病的全球传播是所有地区关注的问题。东南亚地区记录了2021年所有新发结核病例的46%,其次是非洲和西太平洋地区,分别为23%和18%。分别。研究人员一直在寻找天然物质的潜在替代疗法,以解决耐多药(MDR)结核病的令人担忧的增长,这是由于与开发新的治疗方法相关的高成本和目前使用的合成药物的不利副作用。植物化学品由于其对病原体细胞的多靶向能力而显示出作为未来健康援助的有希望的结果。在寻找新药线索时,阿育吠陀和西达医疗系统广泛使用了民族医学工具,包括使用Amalaki(EmblicaofficinalisGaertn。),古杜奇(Tinosporacordifoliawilld。),Sariva(HemidesmusindicusR.Br.),库萨(索苏雷亚·拉帕·法尔克。),姜黄(姜黄。)和绿茶(山茶。).这些来源富含类黄酮,多酚,单宁和儿茶素,已被证明可以降低结核病的风险。在本概述中,我们看看像植物这样的自然来源,藻类和蘑菇帮助研究人员找到了新的药物线索,以及如何通过绘制分子方法和其他方法来支持这些天然来源,帮助他们击败了MDR。
    A large number of people annually lose their lives to tuberculosis (TB), which is an age-old disease caused by the Mycobacterium tuberculosis. The global spread of TB is a concern for all regions. The south-east Asian region recorded 46% of all new TB cases in 2021, followed by the African and western Pacific regions with 23% and 18%, respectively. Researchers are always searching at natural substances for potential alternative therapeutics to tackle the worrisome growth in multi-drug-resistant (MDR) tuberculosis due to the high costs associated with developing new treatments and unfavourable side effects of currently used synthetic pharmaceuticals. Phytochemicals show promising results as a future health aid due to their multi-targeting ability on pathogen cells. In the search for new drug leads, the Ayurvedic and Siddha medical systems have made an extensive use of ethnomedicinal tools, including the use of plants like Amalaki (Emblica officinalis Gaertn.), Guduchi (Tinospora cordifolia willd.), Sariva (Hemidesmus indicus R.Br.), Kustha (Saussurea lappa Falc.), turmeric (Curcuma longa Mal.) and Green tea (Camellia sinensis Linn.). These sources are high in flavonoids, polyphenols, tannins and catechins, has been shown to reduce the risk of TB. In this overview, we look at how natural sources like plants, algae and mushrooms have helped researchers to find new drug leads, and how to back these natural sources through mapping the molecular approaches and other approaches has helped them to defeat MDR.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: English Abstract
    Patients with diseases of the musculoskeletal system are confronted with a large quantity of treatment offers based on methods of complementary medicine. Despite a considerable number of publications on this topic, the scientific evidence is still poor. This article focuses on Ayurvedic medicine (AM), traditional Chinese medicine (TCM), mind-body medicine and homeopathy. These procedures have a longstanding tradition of practice and each claims to have its own theoretical concept; however, the application in the field of rheumatology can only be recommended either for specific entities or, in the case of homeopathy, not at all. In addition, this article summarizes the evidence for dietary recommendations, nutritional supplements and herbal medicine in rheumatology. The latter topics are frequently discussed in the popular press and are a much-debated issue between physicians and patients; however, clear-cut recommendations for the application on a scientific basis are the exception and mainly consist of the endorsement to adhere to the principles of a Mediterranean diet.
    UNASSIGNED: Für Patienten mit Erkrankungen des muskuloskeletalen Systems existiert eine schwer überschaubare Zahl von Behandlungsangeboten aus dem Bereich komplementärer Heilverfahren. Trotz einer beträchtlichen Zahl von Publikationen zu diesem Thema ist die wissenschaftliche Evidenz nach wie vor gering. Der Beitrag widmet sich der ayurvedischen Medizin (AM), der traditionellen chinesischen Medizin (TCM), der Mind-Body-Medizin und der Homöopathie. Auch wenn es sich dabei um Verfahren handelt, die eine lange Anwendungstradition haben und sich auf ein eigenes theoretisches Konzept berufen, kann ihre Anwendung in der Rheumatologie nur für bestimmte Entitäten oder – im Fall der Homöopathie – nicht empfohlen werden. Zusätzlich wird die Evidenz für Diätverfahren, Nahrungsergänzungsmittel und Phytotherapie vorgestellt. Die Letztgenannten treffen in der Laienpresse auf großes Interesse und beanspruchen in der Sprechstunde einen relevanten Anteil an Beratungszeit. Allerdings sind auch hier Anwendungsempfehlungen auf wissenschaftlicher Grundlage die Ausnahme und fokussieren v. a. auf eine vollwertige, an den Prinzipien der Mittelmeerkost orientierte Ernährung.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    民族药理学相关印度传统医学体系,AYUSH(阿育吠陀,瑜伽,Unani,西达,和顺势疗法)具有药典中包含的数千种药用植物的安全使用史(HOSU)的巨大潜力。存在于不同传统使用的药用植物中的植物成分的多目标方法使它们适合用于针对各种感染性病原体的研究的候选者。MAP是一种乳源性病原体,与反刍动物的约翰氏病和克罗恩氏病如人类自身免疫性疾病的发展有关。针对MAP没有可靠的治疗替代方案,留下手术切除肠作为唯一的选择。因此,迫切需要寻找针对这种感染的线索。本研究的目的进行了本综述,以找出有关植物成分对抗鸟分枝杆菌亚种副结核(MAP)的潜力的民族药理学证据,随着潜在的phyto-MAP机制的首次服用抗炎药,免疫调节,以及抗微生物的传统主张。材料和方法我们已经分析和审查了印度的两个主要传统经文的不同卷,即印度的阿育吠陀药典(API)和印度的Unani药典(UPI),分别-根据相关疾病的主张鉴定潜在的抗MAP植物。通过包括GoogleScholar在内的电子数据库,这些植物在过去20年(2002-2022年)的科学出版物中进行了进一步的系统研究,Pubmed,还有Scopus.在体外进行的研究,细胞系,并考虑了体内水平以及植物成分的相关机制。结果共鉴定出70种潜在药用植物。基于民族药理学,已经提出了一种潜在的副结核病(Phyto-paraTB)机制,并且在70种潜在的抗MAP植物中,已经确定了7种具有抗MAP的未来。结论已提出了一种新颖且科学可行的计划,用于解决抗MAP植物,以使用大众信赖的AYUSH药物刺激针对MAP和相关疾病的研究。它可以在耐药病例中用作替代治疗,否则可以被提倡作为现代治疗的佐剂,以更好地管理疾病。
    BACKGROUND: Indian system of Traditional medicine, AYUSH (Ayurveda, Yoga, Unani, Siddha, and Homeopathy) has great potential with a History of Safe Use (HOSU) of thousands of medicinal plants included in pharmacopoeias. The multi-targeted approach of phytoconstituents present in different traditionally used medicinal plants makes them suitable candidates for research against various infective pathogens. MAP which is a dairy-borne pathogen is associated with the development of Johne\'s disease in ruminants and Crohn\'s disease like autoimmune disorders in human beings. There are no reliable treatment alternatives available against MAP, leaving surgical removal of intestines as the sole option. Hence, there exists an urgent need to search for leads against such infection.
    OBJECTIVE: The present review has been conducted to find out the ethnopharmacological evidence about the potential of phytoconstituents against Mycobacterium avium subspecies paratuberculosis (MAP), along with the proposal of a potential phyto-MAP mechanism for the very first time taking anti-inflammatory, immunomodulatory, and anti-microbial traditional claims into consideration.
    METHODS: We have analyzed and reviewed different volumes of the two main traditional scriptures of India i.e. Ayurvedic Pharmacopoeia of India (API) and Unani Pharmacopoeia of India (UPI), respectively-for identification of potential anti-MAP plants based on their claims for related disorders. These plants were further investigated systematically for their scientific publications of the last 20 years (2002-2022) available through electronic databases including Google Scholar, Pubmed, and Scopus. The studies conducted in vitro, cell lines, and in vivo levels were taken into consideration along with the associated mechanisms of phytoconstituents.
    RESULTS: A total of 70 potential medicinal plants have been identified. Based on the ethnopharmacology, a potential phyto-paratuberculosis (Phyto-paraTB) mechanism has been proposed and out of 70, seven potential anti-MAP plants have been identified to have a great future as anti-MAP.
    CONCLUSIONS: A novel and scientifically viable plan has been proposed for addressing anti-MAP plants for stimulating research against MAP and related disorders using mass-trusted AYUSH medicine, which can be used as an alternative remedy in resistance cases otherwise can be advocated as an adjuvant with modern treatments for better management of the disease.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:这篇综述探讨了2型糖尿病(T2DM)与糖尿病诱发的阿尔茨海默病(AD)之间的联系。它强调了两种情况之间的共同病理生理联系和机制,专注于降低胰岛素水平和受体,葡萄糖代谢受损,胰岛素抵抗,线粒体功能障碍,和受AD影响的大脑中的氧化损伤-T2DM的平行方面。该评论认为AD是一种“大脑糖尿病”,“通过抗糖尿病干预得到认知增强的支持。它侧重于传统上使用的印度草药,作为一种手段,以最小的副作用和毒性来管理这两种条件,同时解决发展挑战。
    目的:本研究探讨了DM-AD连接,回顾对这两种疾病都有保护潜力的草药,考虑传统用途和发展挑战。
    方法:研究研究,reviews,以及来自电子数据库和传统书籍的民族植物学和科学数据。
    结果:该研究分析了DM和AD之间的病理生理联系,强调它们相互关联的因素。通过临床前/临床证据,对八种对T2DM和AD具有双重保护作用的阿育吠陀植物进行了全面审查。历史背景,植物成分,并探索了传统的应用。检查使用这些植物的创新配方。来自植物成分的物理化学性质的挑战被强调,促进新型制剂的开发,包括基于纳米技术的输送系统。该研究发现了制定这些疾病治疗方法的障碍。
    结论:该综述显示了所选择的草药对抗这两种疾病的双重潜力,以及它们的传统应用,认可他们的使用。它解决了制定障碍,提出草药疗法的创新输送技术,同时承认他们的限制。审查表明,需要在这一领域加强投资和研究。
    BACKGROUND: This review explores the link between Type 2 Diabetes Mellitus (T2DM) and diabetes-induced Alzheimer\'s disease (AD). It emphasizes the shared pathophysiological links and mechanisms between the two conditions, focusing on reduced insulin levels and receptors, impaired glucose metabolism, insulin resistance, mitochondrial dysfunction, and oxidative damage in AD-affected brains-paralleling aspects of T2DM. The review suggests AD as a \"diabetes of the brain,\" supported by cognitive enhancement through antidiabetic interventions. It focuses on the traditionally used Indian herbs as a means to manage both conditions while addressing developmental challenges.
    OBJECTIVE: This study explores the DM-AD connection, reviewing medicinal herbs with protective potential for both ailments, considering traditional uses and developmental challenges.
    METHODS: Studied research, reviews, and ethnobotanical and scientific data from electronic databases and traditional books.
    RESULTS: The study analyzes the pathophysiological links between DM and AD, emphasizing their interconnected factors. Eight Ayurvedic plants with dual protective effects against T2DM and AD are thoroughly reviewed with preclinical/clinical evidence. Historical context, phytoconstituents, and traditional applications are explored. Innovative formulations using these plants are examined. Challenges stemming from phytoconstituents\' physicochemical properties are highlighted, prompting novel formulation development, including nanotechnology-based delivery systems. The study uncovers obstacles in formulating treatments for these diseases.
    CONCLUSIONS: The review showcases the dual potential of chosen medicinal herbs against both diseases, along with their traditional applications, endorsing their use. It addresses formulation obstacles, proposing innovative delivery technologies for herbal therapies, while acknowledging their constraints. The review suggests the need for heightened investment and research in this area.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • DOI:
    文章类型: Case Reports
    荨麻疹是一种皮肤病,表现为瘙痒引起的红斑性病变,并在皮肤外观无变化的情况下消退。在阿育吠陀,这种情况类似于“Sheetapitta,“涉及Doshas(身体的调节功能因素)的不平衡,并通过Panchakarma等纯化技术进行治疗。认识到这种治疗的重要性,这个案例探讨了阿育吠陀净化疗法的有效性,特别是Shodhana,治疗慢性荨麻疹。
    一名38岁的女性患者有一年的红斑皮疹病史,伴有剧烈瘙痒,全身肿胀,使用抗组胺药并没有消退。最初的医学评估包括全血细胞计数和血清IgE水平,这支持慢性荨麻疹的诊断。
    该患者被送往Panchakarma住院部接受了称为Panchakarma的阿育吠陀净化疗法,其中包括Vamana(治疗性呕吐)等程序,和Virechana(药物清除)。这些疗法是根据患者的体质需求和症状的严重程度量身定制的。
    治疗后的评估显示出显著的改善,荨麻疹活动评分7(UAS7)从42降低到8,血清IgE水平从469IU/ml降低到32.9IU/ml。这些发现证明了治疗对主观和客观参数的影响。
    该案例有效地证明了Shodhana(净化程序),随着支持Shamana(内部药物),提供了一种治疗慢性自发性荨麻疹的替代方法,特别是在对常规疗法无反应的情况下。这种方法不仅缓解了症状,而且解决了阿育吠陀实践中所理解的疾病的根本原因,为进一步研究和临床应用提供了一个有希望的领域。
    UNASSIGNED: Urticaria is a dermatological disorder that manifests as raised erythematous lesions with pruritis and resolves with no changes to the appearance of the skin. In Ayurveda, this condition is similar to \"Sheetapitta,\" which involves an imbalance of Doshas (regulatory functional factors of the body) and is treated through purification techniques like Panchakarma. Recognizing the significance of such treatments, this case explores the effectiveness of Ayurveda purificatory therapies, specifically Shodhana, in managing chronic urticaria.
    UNASSIGNED: A 38-year-old female patient presented with a one-year history of reddish raised skin rashes with intense itching and, swelling all over the body, which did not get subsided by the use of anti-histamines. Initial medical evaluations included a complete blood count and serum IgE levels, which supported the diagnosis of chronic urticaria.
    UNASSIGNED: The patient was admitted to the Panchakarma In-Patient department for a course of Ayurveda purificatory therapies called Panchakarma, which included procedures such as Vamana (therapeutic vomiting), and Virechana (medicated purging). These therapies were tailored to the patient\'s constitutional needs and the severity of the symptoms.
    UNASSIGNED: Post-treatment assessments showed significant improvement, evidenced by reductions in the Urticaria Activity Score 7 (UAS7) from 42 to 8, and a decrease in serum IgE levels from 469 IU/ml to 32.9 IU/ml. These findings demonstrate the impact of the treatment on both subjective and objective parameters.
    UNASSIGNED: The case effectively demonstrates that Shodhana (purificatory procedures), along with supportive Shamana (internal medication), provides an alternative to manage chronic spontaneous urticaria, particularly in cases unresponsive to conventional therapies. This approach not only alleviates symptoms but also addresses the root cause of the ailment as understood in Ayurvedic practice, suggesting a promising area for further research and clinical application.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    草药的临床前毒理学评估是必要的,以确定任何潜在的健康相关的副作用,如果有的话。BPGrit是一种基于阿育吠陀的药物,用于治疗高血压疾病。基于高效液相色谱法的分析显示存在没食子酸,鞣花酸,香豆素,肉桂酸,guggulstoneE,和guggulstoneZ在BPGrit。对于BPGrit的亚急性毒性分析,雄性和雌性Sprague-Dawley大鼠以100、300和1000mg/kg体重/天的剂量重复口服灌胃28天,接下来是14天的恢复期。无死亡率,发病率,在整个研究期间,在BPGrit处理的大鼠中观察到异常临床体征。此外,实验动物的体重和食物消耗习惯在研究期间没有改变.血液学,生物化学,和组织病理学分析未表明在BPGrit处理的大鼠中发生任何异常变化,直至最高测试剂量1000mg/kg体重/天。最后,该研究在Sprague-Dawley大鼠中建立了>1000mg/kg体重/天的BPGrit的“未观察到的不良反应水平”。
    A pre-clinical toxicological evaluation of herbal medicines is necessary to identify any underlying health-associated side effects, if any. BPGrit is an Ayurveda-based medicine prescribed for treating hypertensive conditions. High-performance liquid chromatography-based analysis revealed the presence of gallic acid, ellagic acid, coumarin, cinnamic acid, guggulsterone E, and guggulsterone Z in BPGrit. For sub-acute toxicity analysis of BPGrit, male and female Sprague-Dawley rats were given repeated oral gavage at 100, 300, and 1000 mg/kg body weight/day dosages for 28 days, followed by a 14-day recovery phase. No incidences of mortality, morbidity, or abnormal clinical signs were observed in BPGrit-treated rats throughout the study period. Also, the body weight and food consumption habits of the experimental animals did not change during the study duration. Hematological, biochemical, and histopathological analysis did not indicate any abnormal changes occurring in the BPGrit-treated rats up to the highest tested dose of 1000 mg/kg body weight/day. Finally, the study established the \"no-observed-adverse-effect level\" for BPGrit at >1000 mg/kg body weight/day in Sprague-Dawley rats.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:压力是调节认知健康的已知致病因素,整体福祉和生活质量取决于什么。已显示长期压力会破坏下丘脑-垂体-肾上腺(HPA)轴的平衡。适应原,如Withaniasomnifera(ashwagandha),在阿育吠陀医学中通常用于缓解压力和改善HPA轴功能障碍。这项研究的目的是通过在剂量依赖性临床研究中确认用于压力管理的最低临床验证剂量(125mg/天)来支持根和叶水提取的ashwagandha提取物(WS)在减轻压力中的作用。
    方法:8周,随机化,双盲,我们进行了安慰剂对照研究,以比较三种不同WS提取物剂量(125,250和500mg)的效果.共有131名成年人报名参加,和98个被包括在最终分析中。使用14项感知压力量表(PSS)和生化相关压力参数来测量慢性压力的衰减。
    结果:我们已经表明,在125毫克的剂量下,水性WS提取物(根和叶)可以安全地减少轻度至中度的慢性应激,250毫克,和500毫克/天8周。
    结论:我们的发现证明了这种特征良好的WS(根和叶)水提取物在125mg/天的低剂量下具有减轻压力的能力,以剂量依赖的方式,通过HPA轴的调制。
    背景:本研究已在印度临床试验注册中心(CTRI)注册,注册编号:CTRI/2019/11/022100。
    BACKGROUND: Stress is a known causative factor in modulating cognitive health, which overall well-being and quality of life are dependent on. Long-term stress has been shown to disrupt the balance of the hypothalamic-pituitary-adrenal (HPA) axis. Adaptogens, such as Withania somnifera (ashwagandha), are commonly used in Ayurvedic medicine for stress relief and ameliorating HPA-axis dysfunction. The aim of this study was to support the role of a root and leaf water-extracted ashwagandha extract (WS) in stress reduction by confirming the lowest clinically validated dose for stress management (125 mg/day) in a dose-dependent clinical study in adults with self-reported high stress.
    METHODS: An 8-week, randomized, double-blinded, placebo-controlled study to compare the effects of three different WS extract doses (125, 250 and 500 mg) was performed. A total of 131 adults were enrolled, and 98 were included in the final analysis. Attenuation of chronic stress was measured using the 14-item Perceived Stress Scale (PSS) and biochemical-related stress parameters.
    RESULTS: We have shown that aqueous WS extract (roots and leaves) safely reduces mild to moderate chronic stress at doses of 125 mg, 250 mg, and 500 mg/day for 8 weeks.
    CONCLUSIONS: Our findings demonstrate the stress-reduction capabilities of this well-characterized aqueous extract of WS (root and leaf) at the low dose of 125 mg/day, in a dose-dependent manner, via the modulation of the HPA axis.
    BACKGROUND: This study was registered with the Clinical Trials Registry-India (CTRI) with the registration number: CTRI/2019/11/022100.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    目的:Vyadhikshamatva概念的各个方面已经被彻底探索,突出了它在抵抗疾病表现方面的深远意义,特别是在强直性脊柱炎的背景下。通过检查当前的知识和假设,研究HLA-B27与强直性脊柱炎(AS)之间的关系。努力描绘prakruti(体质)和balam(力量)对疾病表现和进展的影响。
    方法:分析了阿育吠陀文献以及当代研究工作,以将vyadhikshamatva等各个方面相关联,Oja(所有身体元素的最终本质),和balam以及它们对身体防御机制的影响。进行了彻底的文献检索,以通过检查各种假设,如Arthrentogenic肽假说,探索HLA-B27和AS之间的强关联。错误折叠的假设,表面同源二聚体假说,和试图解释HLA-B27在AS中的致病作用的β2微球蛋白假说。除了经典的阿育吠陀文本,像PubMed和Scopus这样的数据库使用诸如Immunity之类的关键字进行搜索,强直性脊柱炎,Vyadhikshamatva,HLA-B27巴拉姆,以及在布尔运算符的帮助下的自身免疫性疾病。
    结果:评论强调了Vyadhikshamatva在疾病预防中的关键作用,特别是影响AS等疾病的表现,尽管有遗传易感性(HLA-B27)。Further,对阿育吠陀概念的理解可以清楚地解释在确定强直性脊柱炎中HLAB27基因阳性作为明确的诊断标准时出现的冲突。
    结论:这种全面的理解将提高对疾病管理中个性化医疗的需求。必须进一步研究以了解遗传因素之间的相互作用(HLAb27),个人宪法,还有他们的vyadikshamatva.
    OBJECTIVE: Various aspects of the concept of Vyadhikshamatva have been thoroughly explored, highlighting its profound significance in resisting disease manifestation, particularly in the context of Ankylosing spondylitis. Investigated the relationship between HLA-B27 and Ankylosing spondylitis (AS) by examining current knowledge and hypotheses Furthermore, efforts were made to portray the influence of prakruti (constitution) and balam (strength) on disease manifestation and progression.
    METHODS: Ayurvedic literature along with contemporary research works was analyzed for correlating various aspects like vyadhikshamatva,oja (The final essence of all body elements), and balam along with their influence on the defensive mechanism of the body. A thorough literature search was conducted to explore the strong association between HLA-B27 and AS by examining various hypotheses like the Arthritogenic peptide hypothesis, the Misfolding hypothesis, the Surface Homodimer hypothesis, and the β2 microglobulin hypothesis that attempts to explain the pathogenic role of HLA-B27 in AS. Alongside classical Ayurvedic texts, databases like PubMed and Scopus were searched using keywords such as Immunity, Ankylosing spondylitis, Vyadhikshamatva, HLA-B27, Balam, and Autoimmune disorder with the help of Boolean operators.
    RESULTS: The review highlighted the critical role of Vyadhikshamatva in disease prevention, particularly in influencing the manifestation of conditions like AS despite genetic predisposition (HLA-B27). Further, the understanding of the Ayurvedic concepts can clearly explain the conflict that has arisen in the determination of the positive HLAB27 gene in Ankylosing Spondylitis as a definite diagnosing criteria.
    CONCLUSIONS: This comprehensive understanding will uplift the need for personalized medicine in disease management. Further research must be needed to understand the interaction between genetic factors (HLAb27), individual constitution, and their vyadikshamatva.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号